INTERESTING COMPANIES FOUND

UGISense (2016, Munich) – Developing antisense therapeutic agents using a proprietary platform technology called Ugimeres. Ugimeres are short oligonucleotide sequences that bind to single-stranded DNA or RNA and halt disease progression at early stage.

HIGHLIGHTS OF THE DAY

  • Alexion shelves an early-stage Sanfilippo B drug, writes off $85M. Read More
  • Rhythm closes $41M to push lead peptide therapy for genetic obesity into phase III trials. Read More
  • Windtree Therapeutics, developing aerosolized KL4 surfactant therapies for respiratory diseases completes $10.5M private offering. Read More
  • Cell cuture technology company Xcell Biosciences announces $12M series A funding round. Read More
  • With Ex-Juno employees on its roster, Seattle’s Silverback Therapeutics raises $10M out of $60M goal. Read More

Leave a Reply